We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Fluidigm

Fluidigm Corporation focuses on the most pressing needs in translational and clinical research, including cancer, imm... read more Featured Products: More products

Download Mobile App




Adaptive Immune Cells in Ulcerative Colitis Revealed by Single-Cell Analyses

By LabMedica International staff writers
Posted on 01 Sep 2020
Inflammatory bowel disease encompasses a spectrum of complex intestinal disorders characterized by dysregulated innate and adaptive immune responses to gut microbiota in genetically susceptible hosts. More...


Inflammatory bowel disease (IBD) is typically categorized as Crohn’s disease or ulcerative colitis (UC) on the basis of anatomic, clinical, and histopathologic criteria. Dysregulated human gut B and T lymphocytes contribute to the immunopathogenesis of UC, a type of IBD characterized by mucosal damage in the colon.

A large team of medical scientists led by those at the University of California at San Diego (La Jolla, CA, USA) obtained intestinal biopsies and peripheral blood from patients undergoing colonoscopy at their facilities. Cells were recovered, washed, filtered, and used for mass cytometry by time of flight (CyTOF, Fluidigm, South San Francisco, CA, USA) or labeled with anti-human CD45 for sorting. CD45+ immune cells were sorted on a FACSAria II (BD Biosciences, San Jose, CA, USA). Intestinal biopsies were mechanically dissociated, then placed into a digestion mixture, filtered, and stained with anti-human CD45. CD45+ immune cells were sorted on a FACSAria II. About 20,000 sorted CD45+ cells were loaded and partitioned into Gel Bead In-Emulsions. Single-cell RNA (scRNA) libraries were sequenced on a HiSeq 4000 (Illumina, San Jose, CA, USA).

The investigators found a suite of ulcerative colitis-related immune cell shifts and clonal relationships, from clonal B cell receptor clonotype clusters and an uptick in plasma cells expressing immunoglobulin G1 to a rise in ZEB2 transcription factor-expressing regulatory T cells in colon tissue. The resulting single-cell sequencing resource revealed heterogeneity among tissue-resident memory T cells (TRM) in UC, including expansion of an inflammatory CD8+ TRM subset expressing the Eomesodermin transcription factor.

The team also flagged informative transcriptional features in CD8+ tissue-resident memory T cells typically tasked with buffeting bacterial infections, defining a handful of transcriptionally distinct clusters of the cells in colon tissue that differed from healthy tissue to tissue affected by ulcerative colitis, including a cluster with more inflamed versions of the CD8+ tissue-resident T cells.

The authors concluded that their study identified alterations in immune cell types and clonal relationships that occur in the context of disease, including plasma cells, Treg cells, γδ T cells, and CD8+ TRM cells, and will enable other investigators to identify additional UC-associated changes in a cell type– and tissue-specific manner for further study. The study was published on August 21, 2020 in the journal Science Immunology.

Related links:
University of California at San Diego
Fluidigm
BD Biosciences
Illumina




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Gastrointestinal Panel
Xpert® GI Panel
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: LVOne uses blood-based biomarkers to detect stroke and identify large vessel occlusion before hospital arrival, providing objective results earlier than traditional assessments. (Photo courtesy of UpFront Diagnostics)

First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage

Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read more

Molecular Diagnostics

view channel
Image: The proposed workflow adds liquid biopsy to detect genetic and molecular signs of cancer in CSF samples already collected during autoimmune encephalitis evaluation. (Image Credit: Shutterstock)

CSF Liquid Biopsy Could Help Distinguish Cancer from Autoimmune Brain Inflammation

Autoimmune encephalitis can cause memory and behavioral changes, seizures, and altered consciousness, but diagnosis can be challenging because cancers involving the brain and central nervous system may... Read more

Microbiology

view channel
Image: Ebola remains a rapidly evolving public health threat with high mortality, underscoring the need for timely diagnosis and decentralized testing closer to patients (Image Credit: Adobe Stock)

Collaboration Targets Blood-Based Ebola Detection Outside Central Laboratories

Co-Diagnostics, Inc. (Salt Lake City, UT, USA) and ReadyGo Diagnostics Ltd. (Bath, UK) have initiated a collaboration to evaluate ReadyGo’s GoCollect with the Co-Dx PCR platform for blood-based molecular... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Galleri is designed to detect cancer-specific methylation patterns across multiple cancer types before symptoms appear, including cancers without recommended screening (Photo courtesy of GRAIL)

Multi-Cancer Early Detection Test Wins FDA Panel Backing for Approval

GRAIL’s Galleri multi-cancer early detection (MCED) test was reviewed by the Molecular and Clinical Genetics Devices Panel of the U.S. Food and Drug Administration’s (FDA) Medical Devices Advisory Committee.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.